Efficacy of the Transversus Abdominis Plane Block on Analgesia After Cephalic Duodeno-pancreatectomy

NCT05546970 | Completed

• 1 other identifier: 8703
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic duodenectomy is one of the treatments offered to patients with neoplastic disease of the pancreas. In France, in 2018, 14,000 duodeno-pancreatectomies were performed, including 140 at the Hautepierre hospital at the Strasbourg University Hospital. Pancreaticoduodenectomy is a major surgery, causing significant postoperative pain that should be minimized through multimodal analgesia involving in particular locoregional anesthesia. Since 2019, the recommendations of the ERAS company concerning ERAS (Improved Rehabilitation After Surgery) after pancreaticoduodenectomy recommend the establishment of thoracic epidural analgesia in order to limit postoperative pain. When there is a contraindication to the placement of a thoracic epidural, in particular due to arterial and/or venous vascular reconstructions requiring potential perioperative curative anticoagulation, the administration of local anesthetic by pericatricial catheter is recommended. recommended. The Transversus Abdominis Plane (TAP) block has proven analgesic efficacy, safety and harmlessness in colorectal surgery.

Conditions

Pancreatic Neoplasms

Keywords

Neoplastic Disease; Pancreatic neoplasia; Pancreatic Neoplasms; Transversus Abdominis Plane Block; TAP-Block; Cephalic duodeno-pancreatectomy

Outcome Measures

Primary Outcomes (1)

• Efficacy of the echo-guided TAP Block on analgesia

  Morphine consumption in the first 24 postoperative hours

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject (≥18 years of age) operated at HUS for cephalic duodeno-pancreatectomy between 01/01/2018 and 01/04/ 2022

You may qualify if:

• Major subject (≥18 years of age)
• Subject operated at HUS for cephalic duodeno-pancreatectomy between 01/01/2018 and 01/04/ 2022.
• Subject who has not expressed an objection to the reuse of their data for scientific research purposes.

You may not qualify if:

• Subject having expressed his/her opposition to participate in the study
• Admission in intensive care unit after the operation
• Morphine treatment at home
• Drug addiction, weaned or not

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Anesthésie, Réanimation et Médecine péri-Opératoire - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Pancreatic Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2022
• First Posted: September 21, 2022
• Study Start: September 1, 2022
• Primary Completion: February 28, 2023
• Study Completion: May 29, 2023
• Last Updated: December 19, 2023

Record last verified: 2023-12

Locations

FR (1)